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Anticoagulation Special Section
Perioperative Anticoagulation
Management in Spine Surgery: Initial
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Anticoagulation Global Survey
Philip Louie, MD1, Garrett Harada, MD1 , James Harrop, MD2, Thomas Mroz, MD3,
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Abstract
Study Design: Cross-sectional, international survey.
Objectives: This study addressed the global perspectives concerning perioperative use of pharmacologic thromboprophylaxis
during spine surgery along with its risks and benefits.
Methods: A questionnaire was designed and implemented by expert members in the AO Spine community. The survey was
distributed to AO Spine’s spine surgeon members (N ¼ 3805). Data included surgeon demographic information, type and region
of practice, anticoagulation principles, different patient scenarios, and comorbidities.
Results: A total of 316 (8.3% response rate) spine surgeons completed the survey, representing 64 different countries. Com-
pleted surveys were primarily from Europe (31.7%), South/Latin America (19.9%), and Asia (18.4%). Surgeons tended to be 35 to
44 years old (42.1%), fellowship-trained (74.7%), and orthopedic surgeons (65.5%) from academic institutions (39.6%). Most
surgeons (70.3%) used routine anticoagulation risk stratification, irrespective of geographic location. However, significant dif-
ferences were seen between continents with anticoagulation initiation and cessation methodology. Specifically, the length of a
procedure (P ¼ .036) and patient body mass index (P ¼ .008) were perceived differently when deciding to begin anticoagulation,
while the importance of medical clearance (P < .001) and reference to literature (P ¼ .035) differed during cessation. For specific
techniques, most providers noted use of mobilization, low-molecular-weight heparin, and mechanical prophylaxis beginning on
postoperative 0 to 1 days. Conversely, bridging regimens were bimodal in distribution, with providers electing anticoagulant
initiation on postoperative 0 to 1 days or days 5-6.
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Conclusion: This survey highlights the heterogeneity of spine care and accentuates geographical variations. Furthermore, it
identifies the difficulty in providing consistent perioperative anticoagulation recommendations to patients, as there remains no
widely accepted, definitive literature of evidence or guidelines.
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Introduction
Venous thromboembolism (VTE) is a preventable cause of
perioperative morbidity and mortality. The incidence of VTE
after spine surgery varies widely, ranging between 0.3% and
31%.1-11 Multiple factors contribute to this heterogeneity.
These studies have consisted of patients undergoing surgery
for elective, trauma, or oncologic indications (as some present
with higher baseline rates of VTE), and also lack consistency in
the method and timing of diagnosis. Given the heterogeneity of
medical comorbidities, spinal pathology, and surgical tech-
niques, a need for patient-specific anticoagulation guidelines
is mounting.
Early patient mobilization, sequential compression devices
(SCDs), and compression stockings are common nonpharma-
cologic approaches to VTE prophylaxis.12-14 Several pharma-
cologic agents exist that are prescribed for VTE prophylaxis,
such as heparin, low-molecular-weight heparin (LMWH), and
warfarin. These medications directly target factors involved in
the coagulation cascade.15-20 Other medications indirectly tar-
get similar factors, such as factor Xa.21-23 A combination of
these modalities are often parts of the multimodal VTE preven-
tion strategy. Unfortunately, pharmacologic VTE prophylaxis
can also cause a postoperative epidural hematoma or persistent
wound drainage leading to higher rates of infection.
Recent practice guidelines have been generated related to
the type and timing of VTE prophylaxis for patients with acute
spinal cord injury, although uncertainty remains regarding the
optimal timing for the initiation of therapy.24 Moreover, there
is no consensus about perioperative VTE prophylaxis for
patients undergoing spine surgery in patients with disorders
other than an acute SCI. The risk of developing a clinically
significant VTE must be balanced with the risk of early post-
operative bleeding and epidural hematoma formation.25-27 Sev-
eral attempts to create surveys have been made to elicit
perioperative VTE prophylaxis patterns. However, several sur-
veys have noted that the use of thromboprophylactic medica-
tions in the perioperative setting differed greatly28,29 and that
there is no clear consensus on its use.30 Previous studies are
limited by small sample sizes that prevent extensive assessment
of risk factors and heterogeneity among anticoagulation meth-
ods. They also do not account for the different perspectives of
spine surgeons globally. In addition, in 2009, the North Amer-
ican Spine Society attempted to create clinical guidelines on
antithrombotic therapies in spine surgery.18 Although compre-
hensive, these guidelines have yet to be widely adopted
worldwide.
Given the lack of consensus surrounding perioperative
anticoagulation management in spine surgery, we conducted
a global survey of spine surgeons to gauge their knowledge,
attitudes, and practices on this topic. These results will shed
light on how spine surgeons manage thromboprophylaxis over
multiple countries, specialties, time in practice, type of prac-
tice, and many other specific variables. We hypothesize that the
survey responses will show heterogeneity in anticoagulation
practices with few instances of general consensus surrounding
perioperative thromboprophylaxis in spine surgery.
Methods
Survey Design
A survey questionnaire was developed, including demographic
information regarding surgeon and their practice, general antic-
oagulation principles, and scenarios based on patient factors,
comorbidities, and region of spine pathology necessitating sur-
gical intervention. The questions were developed by the Global
Spine Journal Editorial Board and the Regional Research
Chairs of AO Spine. Question selection was based on a
Delphi-esque style for consensus, following several rounds of
review before finalization.
Demographics were obtained on geography, specialty train-
ing, time in practice, practice type, and surgical volume. The
general anticoagulation questions focused on current rationale
for anticoagulation following spine surgery, risk stratification
applications, the use of published/unpublished guidelines to
guide treatment, and the use of multidisciplinary teams. The
specific anticoagulation section was further subdivided into
cervical, lumbar, and thoracolumbar surgery. Questions sought
to assess perioperative factors that affect the timing of antic-
oagulation prophylaxis, how the diagnosis of a spinal cord
injury affects thromboprophylaxis, period of bridging (the use
of short-acting anticoagulants during interruption of warfarin
therapy), and individual anticoagulation treatments based on
medical comorbidities and previous episodes of thrombosis
and/or embolus.
The survey was subsequently designed on a SurveyMonkey
platform (San Mateo, CA) and distributed to the AO Spine
membership through emails that classified themselves as inde-
pendently performing spine surgery and who agreed to receiv-
ing such surveys via email (n ¼ 3805 members out of
approximately 6000 members). The survey recipients were
provided a total of 4 weeks to complete the survey. The
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responses were anonymized and stored separately from the list
of respondents.
Statistical Analyses
All statistical analyses were performed with Stata version 13.1
(StataCorp LC, College Station, TX). Graphical representation
of survey responses was performed using RStudio v1.2.1335
(RStudio Inc, Boston, MA). Interpretation and categorization
of all free-response survey answers were made by one indepen-
dent reviewer to group similar categories for analyses. Calcula-
tion of percentages and means was made for count data and
rank-order questions, respectively. Depiction of data was per-
formed using a combination of RStudio’s ggplot2, rworldmap,
PieDonut, and other required packages. Basic statistical anal-
yses were performed to assess significant differences in count
data using a combination of Fisher’s exact and w2 tests. Differ-
ences in continuous variables between groups was assessed
using analysis of variance (ANOVA). The threshold for statis-
tical significance for all tests was established at P < .05.
Results
Overall, 316 spine surgeons from 64 countries completed the
survey (Figure 1). The largest number of responses were from
the United States (12.3%), India (10.1%), and Germany (6.0%).
When stratified by continent, Europe had the largest survey
representation (31.7%), followed by South America/Latin
America (19.9%) and Asia (18.4%).
Respondents were between the ages of 35 to 44 (42.1%) and
45 to 54 (27.2%) years, and were typically fellowship-trained
(74.7%) and orthopedic surgeons (65.5%). Most were within 5
years (26.4%) or 5 to 10 years (23.1%) of completing their
training, and they practiced at academic (39.6%) or combined
Figure 1. Distribution of survey responses by country.
































Willing to adopt guidelines
Yes 151 47.78
Probably yes 139 43.99
Unsure 17 5.38
Probably no 7 2.22
No 2 0.63
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private/academic institutions (46.2%). The vast majority of
respondents performed an estimated 101 to 200 cases per
year (35.4%). Nearly all surgeons answered that they would
likely adopt anticoagulation guidelines, if established
(91.8%; Table 1).
Regarding current practices, most surgeons (70.3%)
admitted to routine anticoagulation risk-stratification tech-
niques, irrespective of geographic location. Of these respon-
dents, the most common risk-stratification method cited use
of a comorbidity-based evaluation (31.5%) followed by the
use of either hospital, national, or other unspecified guide-
lines (14.4%). Overall, reported methods were roughly sim-
ilar between continents, though significant differences were
observed in the number of recipients who reported use of
multiple risk-stratification techniques (P ¼ .01). Among
recipients who reported no use of routine risk-
stratification, when a reason was specified, most reported
indiscriminate anticoagulation use (23.1%). No significant
differences in reporting for risk-stratification abstinence
was noted between continents (Tables 2-4; Figures 2A,
2B, and 2C).
When querying recipients on factors considered during
anticoagulation initiation and cessation, significant differences
were seen in reporting between continents. Specifically, signif-
icant differences in perceived importance of fellowship train-
ing (P ¼ .016), unspecified guidelines (P ¼ .022), and choice
of specialty (P ¼ .025) were observed between continents in
anticoagulation initiation practices, while usage of medical
clearance (P < .001) and reference to the literature (P ¼
.035) differed during anticoagulant cessation. Moreover, within
continents, differences were seen between mean rankings for
various categories for initiation and cessation as well (Tables 5
and 6). Similarly, for specific patient-related factors employed
in initiation of anticoagulation, significant differences in
Table 2. Do You Perform Risk Stratification for Anticoagulation?a
Yes No Unsure Total
All continents 222 78 18 319
Africa 9 3 0 12
Asia 38 16 3 57
Australia 7 1 0 8
Europe 68 22 11 101
Middle East 24 5 3 32
North America 33 8 2 43
South America 43 20 0 63
P valueb .748 .559 .899 —
aVote totals exceed 316 since 2 respondents reported “Yes” and “No.” One
respondent reported “No” and “Unsure.”
bCalculation of P values was performed using a combination of w2 and Fisher
exact tests.








of Others Miscellaneous Total
All continents 88 70 32 17 8 7 222
Africa 2 4 0 0 3 0 9
Asia 18 11 2 4 1 2 38
Australia 3 3 1 0 0 0 7
Europe 29 17 15 4 1 2 68
Middle East 12 9 2 1 0 0 24
North America 10 10 4 5 2 2 33
South America 14 16 8 3 1 1 43
P valuea .626 .476 .240 .646 .010 .840 —
aCalculation of P values was performed using Fisher exact test. Bolded value indicates statistical significance at P < .05.














All continents 31 11 18 12 2 3 1 78
Africa 0 0 2 1 0 0 0 3
Asia 8 3 1 3 2 0 0 17
Australia 1 0 0 0 0 0 0 1
Europe 6 3 8 5 0 1 0 23
Middle East 2 0 0 2 0 1 0 5
North America 3 2 3 1 0 0 0 9
South America 11 3 4 0 0 1 1 20
P valuea .260 .949 .094 .102 .276 .456 .705 —
aCalculation of P values was performed using Fisher exact test.
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importance of length of operation (P ¼ .036) and body mass
index (P ¼ .008) were also observed by geographic location
(Table 7; Figures 3A, 3B, and 3C). Interestingly, no significant
differences were seen between continents regarding anticoagu-
lation methodology employed in the setting of spinal cord
injury (Tables 8 and 9).
Regarding techniques employed during various hypothetical
scenarios, the vast majority of providers noted use of mobiliza-
tion techniques (range: 71-82 votes), LMWH (range: 62-77
votes), and mechanical prophylaxis (SCD range: 39-46 votes;
compression socks range: 35-44 votes) irrespective of the given
patient history (Table 10). Similar trends were observed even
where patients were utilizing prescribed anticoagulation preo-
peratively (Table 11).
Last, when queried on timing of anticoagulant initiation (for
patients not previously on anticoagulation), the vast majority of
respondents noted initiation on postoperative day 1 (range: 22-
25 votes), followed by postoperative day 0 (range: 9-22 votes;
Table 12; Figure 4). Conversely, bridging regimens appeared
bimodal in distribution, with most providers electing initiation
of aspirin, warfarin, or another agent on postoperative day 1
(range: 13-26 votes) or day 0 (range: 11-28 votes), as well as on
day 5 (range: 8-20 votes) or day 6 and beyond (range: 7-15
votes; Table 13; Figures 5A and 5F).
Figure 2. (A) Overall responses by continent. (B) Yes responses. (C) No responses.
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Discussion
Timing and use of perioperative thromboprophylaxis is contro-
versial given the lack of consensus on best strategies. This topic
remains challenging given the heterogeneity in patient presen-
tation and difficulties in balancing the risks of developing clini-
cally significant VTE versus early postoperative bleeding. As
the largest survey to directly focus on perioperative anticoagu-
lation practices in spine surgery to date, we brought to light the
heterogeneity in practices worldwide. Most important, nearly
all surgeons answered that they would likely adopt anticoagu-
lation guidelines, if established (91.8%). Most surgeons
(70.3%) admitted to routine anticoagulation risk-stratification
techniques, irrespective of geographic location. The most com-
mon risk-stratification method used a comorbidity-based evalua-
tion (31.5%) followed by the use of guidelines (14.4%). Among
recipients who did not use any routine risk-stratification, when
Table 5. Mean Importance for Factors Influencing Anticoagulation Initiationa.
Expert Opinion Fellowship Training Guidelines Specialty Studies
P ValuebMean Rank Mean Rank Mean Rank Mean Rank Mean Rank
Africa 2.670 2.580 3.080 3.080 3.580 .458
Asia 3.120 3.070 3.140 2.780 2.880 .459
Australia 4.130 3.130 3.380 2.250 2.130 .021
Europe 3.380 3.410 3.230 2.780 2.200 <.001
Middle East 2.910 2.590 3.440 3.150 2.910 .175
North America 3.720 3.050 3.070 2.350 2.810 <.001
South America 2.970 3.480 3.300 2.650 2.600 <.001
P valueb .923 .016 .022 .025 .080 —
aCategories were ranked by respondents on a scale from 1 (highest influence) to 5 (lowest influence).
bCalculation of P values was performed using ANOVA. Bolded values indicate statistical significance at P < .05.
Table 6. Mean Importance for Factors Influencing Cessation of Anticoagulationa.
Other Med-Clearance Previous Training Literature
P Valueb# Mean Rank Mean Rank Mean Rank
Africa 2 1.080 1.920 2.170 .017
Asia 6 1.980 1.910 1.980 .905
Australia 0 2.000 2.130 2.500 .298
Europe 2 2.320 1.990 2.210 .012
Middle East 2 2.130 2.000 2.380 .165
North America 3 2.440 2.260 2.400 .481
South America 1 2.480 1.820 2.380 <.001
P valueb <.001 <.001 .279 .035 —
aCategories were ranked by respondents on a scale from 0 (no influence) to 3 (high influence).
bCalculation of P values was performed using a combination of Fisher’s exact test and ANOVA. Bolded values indicate statistical significance at P < .05.
Table 7. Mean Importance for Patient-Specific Factors Influencing Initiation of Anticoagulationa.
Other Length of Operation Number of Levels EBL Drain Output Mobility BMI
P Valueb# Mean Rank Mean Rank Mean Rank Mean Rank Mean Rank Mean Rank
Africa 0 2.375 1.875 1.250 1.250 2.750 2.500 <.001
Asia 1 1.346 1.259 1.222 1.185 2.519 2.074 <.001
Australia 0 1.000 2.000 1.000 2.000 0.000 1.000 —
Europe 3 1.000 0.905 1.095 0.929 2.000 1.857 <.001
Middle East 0 1.364 1.273 1.455 1.364 2.727 2.636 .015
North America 4 0.929 1.000 1.286 1.231 2.071 1.357 .093
South America 1 1.409 1.227 1.273 1.318 2.478 2.348 <.001
P valueb <.001 .036 .239 .966 .710 .076 .008 —
Abbreviations: EBL, estimated blood loss; BMI, body mass index.
aCategories were ranked by respondents on a scale from 0 (no influence) to 3 (high influence).
bCalculation of P values was performed using a combination of Fisher’s exact test and ANOVA. Bolded values indicate statistical significance at P < .05.
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a reason was specified, most reported indiscriminate anticoa-
gulation use (23.1%). Significant differences were observed in
perceived importance of fellowship training, unspecified
guidelines, and choice of specialty between continents in antic-
oagulation initiation practices. While usage of medical clear-
ance and reference to the literature differed when considering
timing of anticoagulant cessation. For specific patient-related
factors employed in initiation of anticoagulation, significant
differences in importance of length of operation and body mass
index were also observed by geographic location. Interestingly,
no significant differences were seen between continents regard-
ing anticoagulation methodology employed in the setting of
spinal cord injury.
The vast majority of providers used mobilization techniques
(range: 71-82 votes), LMWH (range: 62-77 votes), and
mechanical prophylaxis (SCD range: 39-46 votes; compression
socks range: 35-44 votes) irrespective of the given patient his-
tory. Similar trends were observed even where patients were
Figure 3. (A) Ranking of importance for factors influencing anticoagulation initiation. (B) Ranking of factors influencing anticoagulation
cessation. (C) Ranking of patient-specific factors influencing anticoagulation initiation.
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utilizing prescribed anticoagulation preoperatively. The vast
majority of respondents who used chemoprophylaxis initiated
it on postoperative day 1 (range: 22-25 votes), followed by
postoperative day 0 (range: 9-22 votes). Conversely, bridging
regimens appeared bimodal in distribution, with most providers
electing initiation of aspirin, warfarin, or another agent on post-
operative day 1 (range: 13-26 votes) or day 0 (range: 11-28
votes), as well as on day 5 (range: 8-20 votes) or day 6 and
beyond (range: 7-15 votes).
Only a limited number of surveys have been published that
describe perioperative VTE prophylaxis patterns. In a survey
created for spine and trauma-trained surgeons, Ploumis et al28
concluded that spine trauma surgeons do not routinely use
chemical prophylaxis after cervical spine surgery, and that the
use of thromboprophylaxis was tailored to the risk factors
involved with each patient’s presentation. However, this survey
consisted of only 47 surgeons focusing primarily on patients
presenting following spine trauma. Based on a survey of 40
spine surgeons practicing in Switzerland, Baschera et al29 con-
cluded that the administration and discontinuation of thrombo-
prophylactic medications in the perioperative setting differed
vastly between different units and surgeons. This survey
focused on the decision to start several anticoagulation
Table 8. Spinal Cord Injury.
Yes No Total
All continents 75 47 122
Africa 4 3 7
Asia 15 11 26
Australia 1 0 1
Europe 23 18 41
Middle East 8 3 11
North America 9 4 13
South America 15 8 23
P valuea .48 .48 —
aCalculation of P values was performed using Fisher’s exact tests.
Table 9. Anticoagulation Methods when Considering Spinal Cord Injury.
Start Agent Earlier Increase Dose Change Agent Combination of Others Miscellaneous Total
All continents 54 9 3 6 3 75
Africa 4 0 0 0 0 4
Asia 12 2 1 0 0 15
Australia 1 0 0 0 0 1
Europe 14 5 0 2 2 23
Middle East 4 1 1 2 0 8
North America 7 0 1 0 1 9
South America 12 1 0 2 0 15
P valuea .646 .776 .298 .426 .715 —
aCalculation of P values was performed using Fisher’s exact tests.















































9 82 45 35 50 5 2 2 2 2 0 1 1
Hx of deep vein
thrombosis
4 77 46 49 67 13 7 7 0 2 0 4 3
Hx of superficial
thrombophlebitis
5 78 47 46 63 19 6 7 0 2 0 1 3
Hx of pulmonary
embolism
4 75 52 40 70 20 8 5 0 4 0 11 5
Hx of atrial
fibrillation
8 71 43 37 63 13 8 6 1 4 2 2 3
Hx of coronary
artery disease
10 72 44 37 62 14 8 17 2 3 3 2 5
Abbreviations: SCD, sequential-compression device; LMWH, low-molecular-weight heparin; SCH, subcutaneous heparin; ASA, aspirin; bid, twice daily; IVC,
inferior vena cava; Hx, history.
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medications based on various surgeries. However, the survey
was distributed in only one country, which may limit general-
izability. Similarly, 8 different clinical scenarios were pre-
sented to 50 spine surgeons at a British Association of Spine
Surgeon by Bryson et al.30 This group concluded that there was
no clear consensus in thromboprophylaxis in any of the sur-
geries. These findings highlight the discrepancies and uncer-
tainties, likely attributable to the paucity of literature
examining VTE in spinal surgery. Last, in 2009, the North
American Spine Society attempted to create clinical guidelines
on antithrombotic therapies in spine surgery.18 Albeit compre-
hensive, these guidelines have yet to be widely adopted; as only
14% of our respondents described following hospital, national,
or other unspecified guidelines.
The results of this survey highlights the lack of consensus on
various aspects of thromboprophylaxis in spine surgery.
Although a large percentage of respondents subscribed to rou-
tine anticoagulation risk-stratification techniques, reported
methods differed largely irrespective of geographic location.
Additionally, when querying respondents on factors considered
during anticoagulation initiation and cessation, significant dif-
ferences were seen in reporting between geographic locations
of practice. Specifically, the utilization of medical clearance
and adherence to the practices described in literature also
widely varied geographically. Among recipients who reported
no use of routine risk-stratification, when a reason was speci-
fied, most reported indiscriminate anticoagulation use. One
area in which there was relative agreement was the approach
to thromboprophylaxis in the setting of spinal cord injury
(SCI). Patients with acute SCI have been shown to present with
the highest risk of VTE among hospitalized patients, ranging
from 50% to 100% in untreated patients, and pulmonary embo-
lism is the third most common cause of mortality in these
patients.31-33 The global adherence to thromboprophylactic
principles in SCI patients are likely a result of the various
well-studied and widely established/distributed recommenda-
tions and protocols for this presentation.24,34-37
Despite the large amount of data published on specific
thromboprophylactic therapies for various spine surgery
indications, well-established guidelines and algorithms
have had difficulty gaining widespread acceptance and
adherence.2,15-18,20-23,38-43 Although spine surgery VTE
prophylaxis recommendations from North American Spine
Society and American College of Chest Physicians have been











































Hx of deep vein
thrombosis
2 76 42 44 77 20 9 6 0 2 1 6 7
Hx of pulmonary
embolism
3 74 46 40 75 20 10 5 0 1 0 11 7
Hx of atrial
fibrillation
3 72 42 35 71 17 16 7 0 4 1 3 7
Hx of coronary
artery disease
6 67 39 35 71 15 5 12 2 4 1 1 7
Artificial heart
valve
3 71 41 41 67 18 20 12 1 3 2 0 13
Stent 6 70 39 36 62 15 9 18 1 6 3 0 12
Abbreviations: SCD, sequential-compression device; LMWH, low-molecular-weight heparin; SCH, subcutaneous heparin; ASA, aspirin; bid, twice daily; IVC,
inferior vena cava; Hx, history.
Table 12. Start Time (Days) for New Anticoagulation Regimen.
Day 0 Day 1 Day 2 Day 3 Day 5 Day 7 Day 8þ No AC NA
Scenarios # Votes # Votes # Votes # Votes # Votes # Votes # Votes # Votes # Votes
No thromboembolic history 9 23 1 2 0 1 2 24 2
Hx of deep vein thrombosis 22 25 1 3 1 0 3 8 1
Hx of superficial thrombophlebitis 16 25 1 2 0 0 3 17 0
Hx of atrial fibrillation 18 23 3 2 2 1 3 11 1
Hx of coronary artery disease 18 22 1 3 2 0 5 12 1
Abbreviations: NA ¼ not applicable, no response given; Hx, history.
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Figure 4. Start date for new anticoagulation regimen.
Table 13. Bridge Time (Days) for Previous Anticoagulation Regimen.
Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6þ No AC NA
Scenarios # Votes # Votes # Votes # Votes # Votes # Votes # Votes # Votes # Votes
Hx of deep vein thrombosis
ASA 22 26 8 4 2 8 9 3 0
Warfarin 17 17 6 13 2 12 12 2 1
Other 18 21 7 7 2 11 8 6 2
Hx of pulmonary embolism
ASA 28 18 6 5 2 9 9 4 1
Warfarin 22 13 9 9 1 13 11 2 2
Other 23 14 8 8 2 11 7 5 4
Hx of coronary artery disease
ASA 23 22 4 3 2 9 13 2 4
Warfarin 14 16 7 8 2 17 11 4 3
Plavix 11 19 4 7 0 20 15 3 3
Other 12 20 7 7 1 13 8 9 5
Hx of atrial fibrillation
ASA 24 19 3 6 1 8 12 5 4
Warfarin 15 18 7 10 1 13 12 2 4
Other 17 18 5 7 1 14 8 7 5
Hx of artificial heart valve
ASA 21 13 8 7 2 12 8 6 5
Warfarin 18 15 10 11 1 10 9 2 6
Plavix 19 13 5 9 1 15 13 2 5
Other 21 13 8 7 2 12 8 6 5
Hx of stent
ASA 24 21 4 2 2 10 11 3 5
Warfarin 17 14 8 12 1 13 9 3 5
Plavix 14 16 3 10 1 16 15 1 6
Other 16 16 7 6 1 14 9 6 7
Abbreviations: NA, not applicable, no response given; Hx, history; ASA, aspirin.




































































































































































































































































































published, these groups describe “spine surgery” as a broad
category, not taking into account the differing VTE and bleed-
ing complication risks associated with specific surgical proce-
dures and the location in the spine.18,44 To this point, Eskildsen
et al45 worked to develop an algorithm for thromboprophylaxis
in spine surgery. This group created a score based on patient-
related and surgery-specific risk factors for elective spine sur-
geries. This algorithm has difficulty addressing scenarios in
which patients are unable to receive standard prophylaxis and
fails to provide a score for some spine surgeries. Nonetheless,
this algorithm may help guide spine surgeons when deciding on
thromboprophylaxis in the majority of clinical situations.
Despite these attempts at creating widely accepted recommen-
dations and algorithms, this survey shows that reference to
these published items is not commonly practiced globally. The
question remains how we can fundamentally address thrombo-
prophylaxis as a spine community and develop a widely
accepted algorithm or guideline to reference worldwide.
Although difficult, future prospective studies are necessary to
determine whether certain recommendations and algorithms
can improve outcomes in VTE and bleeding complication rates
following common spine surgeries. We plan to use the infor-
mation from this survey to better understand global-, training-,
and practice-specific indications for perioperative thrombopro-
phylaxis to design a prospective randomized trial that can
develop future guidelines and algorithms.
As with any survey, there are limitations to our current
survey and its findings. The survey distribution was limited
to current spine surgeon members of the AO Spine network
that opted-in to receive email notifications, survey requests
falling into this category. As such, there is still questionable
generalizability, especially in regions in which there were
very few or no respondents, and potential selection bias that
may represent a unique make-up of those spine surgeons opt-
ing to receive the survey as opposed to those that did not. The
survey was sent out to 3805 spine surgeons worldwide; how-
ever, only 316 surgeons responded (8.3%). Although the
response rate may appear low, perhaps we have captured
respondents who take special interest in this topic and have
placed greater thought to their anticoagulation practices. Pre-
vious studies have described that a low response rate does not
necessarily mean the study results have low validity, they
simply indicate a greater risk of this. Therefore, response rates
can be informative, but independently should not be consid-
ered a good proxy for study validity.46-48 Furthermore, such a
response rate affiliated with AO Spine surveys distributed to
the membership have been consistent. Given the length limit
of surveys in general, we were not able to capture all of the
possible patient comorbidities, specific spine surgeries, nor
pharmaceutical options. However, given the variety of unique
presentations and treatment practices worldwide, our goal was
to capture the majority of spine surgeons. Although these
limitations exist, this remains the largest, international survey
to date focused on perioperative anticoagulation practices
during spine surgery.
Conclusions
This AO Spine Anticoagulation Global Survey is the largest to
date focusing on perioperative anticoagulation attitudes, prac-
tices, and beliefs among spine surgeons worldwide. Through
the distribution of this large, global survey directly focused on
perioperative anticoagulation practices in spine surgery, our
study highlights the heterogeneous practices across geography,
specialties, time in practice, type of practice, and several other
variables. The one area of agreement across various back-
grounds is the thromboprophylaxis treatment plan in patients
presenting with spinal cord injury. This survey raises aware-
ness and quantitatively highlights the difficulty in providing
consistent perioperative anticoagulation recommendations to
patients as there have been no widely accepted guidelines to
date. Future studies will utilize this data to better understand
global-, training-, and practice-specific indications for perio-
perative thromboprophylaxis to design robust future study
designs, such as prospective randomized trials, that can
develop future guidelines and algorithms or the need for expert
group consensus recommendations for anticoagulation
management.
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